CMO Frontida invests equity in Oncoceutics to establish long-term relationship

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/scyther5)
(Image: Getty/scyther5)
Frontida BioPharm has made an equity investment in Oncoceutics as part of a product development and commercialization agreement to advance the company's lead compound.

The Philadelphia, PA-headquartered contract manufacturing organization (CMO) will develop and scale-up the finished product manufacturing process for Oncoceutics lead compound, ONC201, an antagonist of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2).

According to the company, the molecule is the first designed to target this receptor specifically for oncology and is currently in Phase II clinical trials for select advanced cancers.

This is a complementary partnership that provides significant benefits to both companies, including bringing this life-saving therapy to patients​,” said Ron Connolly, Chief Operations Officer of Frontida BioPharm.

"Oncoceutics has seen some remarkable patient outcomes and this partnership allows us to use our development and manufacturing capabilities to bring Oncoceutics’ therapy to the market​," he told us.

The project initiates Frontida’s relationship with Oncoceutics, which also includes an equity investment.

We made an equity investment because we believe in this molecule and wanted to establish a long-term mutually beneficial relationship with Oncoceutics​,” Connolly explained.

Frontida plans to continue with the development and manufacturing program of the molecule and "seeing it through to FDA approval​,” said Connolly, who added that the company also hopes to collaborate with Oncoceutics on other programs on their platform. 

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers